| By PR Newswire | Article Rating: |
|
| September 27, 2012 10:36 AM EDT | Reads: |
139 |
TORONTO, Sept. 27, 2012 /CNW/ - RepliCel Life Sciences Inc.'s common shares (RP) have been approved for listing on CNSX.
RepliCel is developing and patenting a new hair follicle cell replication technology that has the potential to become the first autologous cellular treatment for hair loss in men and women.
Listing and disclosure documents will be available in the Listings Disclosure Hall .
Trading Date: Monday, October 1, 2012
Symbol: RP
CUSIP: 76027P 10 3
ISIN: CA 76027P 10 3 6
SOURCE Canadian National Stock Exchange (CNSX)
Published September 27, 2012 Reads 139
Copyright © 2012 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

